




Patent Application  
Attorney Docket No. PC10754AJTJ

1615  
TFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:  
Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 14 day of Dec. 2005

By

  
(Signature of person mailing)  
Patricia Citchfield  
(Typed or printed name of person)

PC10754A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
APPLICANTS:

William J. Curatolo, et al. : Group Art Unit: 1615  
Examiner: B. M. Fubara

PATENT NO.: 09/918,127 :

FOR: **Pharmaceutical Compositions of  
Cholesteryl Ester Transfer Protein Inhibitor** :

FILED: July 30, 2001

-----  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.


12/16/2005 YPOLITE1 00000053 161445 09918127

01 FC:1806 180.00 DA

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: Dec. 14, 2005

  
James T. Jones  
Attorney for Applicant(s)  
Reg. No. 30,561

Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 441-4903

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC10754AJTJ				SERIAL NO. 09/918,127			
APPLICANT William J. Curatolo, et al.									FILING DATE July 30, 2001				GROUP 1615			

OFFICE  
 DEC 16 2005  
 RECEIVED  
 REMARKS

U.S. PATENT DOCUMENTS														
EXAMINER	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	5	9	4	2	6	3	1	24 Aug 1999	Deck et al	549	294		
	US	5	4	7	4	9	9	3	12 Dec 1995	Rubin et al	514	192		
	US	5	4	4	6	2	0	7	29 Aug 1995	Pomponi et al	568	633		
	US	5	0	9	3	3	7	1	3 March 1992	Quinn et al	514	682		
	US	6	1	7	7	1	0	1	23 Jan 2001	Martino et al	424	464		
	2003	0	1	7	0	3	0	9	11 Sept 2003	Babcock et al	424	486		
	2003	0	0	9	1	6	4	3	15 May 2003	Friesen et al	424	486		
	2003	0	0	5	4	0	3	8	20 March 2003	Crew et al	424	486		
	US	6	7	6	3	6	0	7	20 July 2004	Beyerinck et al	34	372		
	US	5	7	1	4	5	0	6	3 Feb 1998	Fisher et al	514	352		
	US	4	9	8	3	5	9	3	8 Jan 1991	Miyajima et al	514	110		

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EP	0	5	8	0	8	6	0	22 Oct 1997	EPO	A61K	9/14		
	EP	0	3	4	4	6	0	3	23 Oct 1991	EPO	A61K	31.675		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
			Bisgaler et al., Lipids, vol. 29, no. 12, pgs 811-818, 1994											
			Martin et al., Physical Pharmacy, Physical Chemical Principles in the Pharmaceutical Sciences, 1969, 2 ed. Chapter 4, pg 85											
			Kitahara et al., Japan. Journ. Pharmacol, vol. 69, issue 2, pgs 101-109, 1995											
			Toyoda et al., Japan Journ. Pharmacol. Vol. 103m, issue 5, pgs 231-239, 1994											

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.